Haemonetics says FDA clears vascular closure device
Haemonetics announced FDA approval for its PerQseal Elite device, which seals arterial openings in heart and vascular procedures. The company acquired the technology via its 2026 purchase of Vivasure Medical. Shares rose 1.2% in extended trading. Additional clinical data will be presented at an upcoming conference.
How this was made
The 30-second read
Why it matters
Regulatory clearance validates the acquisition and may accelerate revenue from the new device.
Market read
First‑report FDA approval provides a fresh catalyst for Haemonetics, likely supporting a modest price gain.
What to watch
Potential competition from established closure devices and pricing pressure.
Background
Haemonetics acquired Vivasure Medical in Jan 2026, gaining the technology behind PerQseal Elite.
Ticker impact
FDA cleared Haemonetics' PerQseal Elite vascular closure device, a new product approval.
modest upside as market prices in the regulatory clearance
First report of FDA clearance; small but positive catalyst for a mid‑cap medical device maker.
Market effects
May lift sentiment for vascular closure and broader interventional device sector.
U.S. medical device market sees a new cleared product.
Limited to device manufacturers; no broad macro effect.
Counterpoint
Approval impact could be muted if adoption is slow or reimbursement issues arise.
Key entities
- CompanyHaemonetics
Medical technology firm providing blood management and interventional products.
- CompanyVivasure Medical
Ireland‑based developer of the PerQseal Elite device.
